This project aims to develop blood-based protein biomarker panels for the early detection of breast and/or other cancer types.
In a recently published study, we have prioritized a panel of candidate breast cancer blood protein biomarkers (PMID: 35767427) using state-of-the-art targeted mass spectrometry methods. To further refine and prioritize biomarker candidates for assay development for clinical usage, we propose to analyze the UK Biobank Pharma Proteomics data, an excellent resource for screening and validating early detection biomarker candidates for cancers with moderate to high incidence rates. Specifically, we will conduct comprehensive statistical analyses to identify/prioritize blood proteins whose abundances were linked to prevalent and/or incident cancer events for breast, prostate, colon, lung, and other cancer types.
This project fully complies with UKB’s AI guidance in fairness, transparency, and accountability. If we develop any proprietary models, they will return derived parameters to UKB and avoid generating outputs that risk re-identification. No participant-level data will be used in any generative AI model or made publicly accessible.
